Analysts at Barclays Capital Kept their “Overweight” rating for Virgin Money Holdings UK Plc (LON:VM) with GBX 360.00 Target; Fibrocell Science, Inc. (FCSC) Had 5 Bullish Analysts

Virgin Money Holdings (LON:UK plc) Logo

Among 6 analysts covering Fibrocell Science (NASDAQ:FCSC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Fibrocell Science had 13 analyst reports since September 28, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Tuesday, September 26 with “Buy”. The firm earned “Buy” rating on Thursday, October 5 by H.C. Wainwright. H.C. Wainwright maintained Fibrocell Science, Inc. (NASDAQ:FCSC) rating on Tuesday, January 30. H.C. Wainwright has “Buy” rating and $6.0 target. The firm earned “Buy” rating on Tuesday, January 16 by H.C. Wainwright. On Monday, March 19 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) has “Neutral” rating given on Monday, September 28 by Wedbush. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Tuesday, March 6 report. The firm has “Buy” rating given on Friday, June 9 by H.C. Wainwright. TH Capital initiated it with “Buy” rating and $14.0 target in Tuesday, December 22 report. Roth Capital initiated the shares of FCSC in report on Tuesday, December 22 with “Buy” rating. See Fibrocell Science, Inc. (NASDAQ:FCSC) latest ratings:

19/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
06/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
30/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain

In a research report issued to investors and clients on today, Barclays Capital maintained their “Overweight” rating on Virgin Money Holdings UK Plc (LON:VM)‘s stock. The price target would indicate a potential upside of 35.67% from firm’s current price.

The stock increased 7.05% or $0.04 during the last trading session, reaching $0.65. About 182,005 shares traded. Fibrocell Science, Inc. (NASDAQ:FCSC) has declined 72.30% since April 16, 2017 and is downtrending. It has underperformed by 83.85% the S&P500.

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company has market cap of $18.43 million. The companyÂ’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It currently has negative earnings. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.

Virgin Money Holdings plc engages in the retail banking business primarily in the United Kingdom. The company has market cap of 1.18 billion GBP. The firm operates through Mortgages and Savings; Credit Cards; and Financial Services divisions. It has a 7.08 P/E ratio. The firm offers current accounts; savings accounts, including cash ISAs and fixed rate bonds; residential and buy-to-let mortgages; credit, balance and money transfer, and prepaid cards; home, travel, life, car, and pet insurance; personal, children, and workplace pensions, as well as other pensions and retirement products; investments comprising stocks and shares ISAs, and investment funds, as well as financial planning products; and international money transfers and travel money products.

The stock increased 0.72% or GBX 1.9 during the last trading session, reaching GBX 265.5. About 220,636 shares traded. Virgin Money Holdings (LON:VM) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Fibrocell Science, Inc. (NASDAQ:FCSC) Ratings Chart